Hazlett Burt & Watson Inc. Has $2.26 Million Position in Johnson & Johnson (NYSE:JNJ)

Hazlett Burt & Watson Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 14,403 shares of the company’s stock after selling 123 shares during the period. Johnson & Johnson accounts for about 1.5% of Hazlett Burt & Watson Inc.’s portfolio, making the stock its 9th largest holding. Hazlett Burt & Watson Inc.’s holdings in Johnson & Johnson were worth $2,259,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $27,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $37,000. Tower View Wealth Management LLC raised its stake in Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares in the last quarter. Creative Capital Management Investments LLC raised its position in shares of Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Finally, Altshuler Shaham Ltd raised its position in shares of Johnson & Johnson by 37.8% in the 3rd quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after buying an additional 87 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on JNJ shares. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 13th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Raymond James upped their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.8 %

NYSE:JNJ opened at $147.57 on Friday. The firm’s fifty day moving average is $157.24 and its 200-day moving average is $156.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The firm has a market cap of $355.61 billion, a P/E ratio of 10.69, a P/E/G ratio of 2.50 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period in the prior year, the firm posted $2.35 EPS. The company’s quarterly revenue was down 9.7% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.